Showing 1261-1270 of 1395 results for "".
- Bausch Health Continuing Process Toward Separating Bausch + Lombhttps://modernod.com/news/bausch-health-continuing-process-toward-separating-bausch-lomb/2481048/Bausch Health Companies announced it is moving toward separating Bausch + Lomb after transferring common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing wholly-owned unrestricted subsidiary of the company.
- Ocuphire Extends US Patent Protection for Drug Candidate Nyxol for Reversal of Mydriasis by 5 More Years Into 2039https://modernod.com/news/ocuphire-extends-us-patent-protection-for-drug-candidate-nyxol-for-reversal-of-mydriasis-by-5-more-years-into-2039/2481011/Ocuphire Pharma announced the issuance of a new U.S. Patent (No. 11,400,077), which provides added intellectual property protection for the company’s late-stage product candidate, Nyxol (phentolamine mesylate), with claims directed to methods for treating mydriasis using phentolamine m
- High-Tech Imaging Offers New Way to Detect Signs of Early Glaucomahttps://modernod.com/news/high-tech-imaging-offers-new-way-to-detect-signs-of-early-glaucoma/2481008/A new, noninvasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE). The study was published in the July/August issue of Op
- Study: AMD Strongly Associated With Heart Disease and Strokehttps://modernod.com/news/study-blinding-eye-disease-is-strongly-associated-with-heart-disease-and-stroke/2480958/Patients with a specific form of age-related macular degeneration (AMD) are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai. This study, published in the July issue of Retina, is the first t
- Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiologyhttps://modernod.com/news/nicox-announces-publication-of-ncx-470-results-demonstrating-improvements-to-ocular-hemodynamics-and-retinal-cell-physiology-1/2480951/Nicox SA announced that the results from studies on the beneficial effects of NCX 470 in a nonclinical model of endothelin-1 (ET-1)-induced ischemia/reperfusion damage of the optic nerve head and retina have been published online in the peer-reviewed Journal of Ocular Pharmacology and Therape
- Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabeticshttps://modernod.com/news/ocuphire-granted-new-us-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics/2480941/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330, for diabetic eye disease. In addition, a new publication supporting the nov
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-omni-surgical-system-in-pseudophakic-eyes-with-open-angle-glaucoma/2480722/Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject (Glaukos), in
- Bunkers That Save Sight? UConn Researchers Take a Close Lookhttps://modernod.com/news/bunkers-that-save-sight-uconn-researchers-take-a-close-look/2480693/Chronically stressing the retina can weaken it and damage our ability to see. But retinal cells have a remarkable ability to wall off damage, a team of neuroscientists led by UConn Health reports in the 1 March issue of PNAS. The w
- NIH Researchers Develop First Stem Cell Model of Albinism to Study Related Eye Conditionshttps://modernod.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in the January issue of the journal Stem Cell